Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. Patient monitoring companies within the ...

DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...

The UBS CIO Americas wealth management equity sector strategy team came out and spotlighted its 30 most preferred stocks ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...

Dexcom (Nasdaq:DXCM) has a new chief commercial officer with significant experience at another major medtech company.

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up ...

Of the hundreds of millions of people living with diabetes, most liv. Dexcom wants to make sure they have tools to manage it.